The packet lists FANCA as the associated gene, located on chromosome 16, and ClinGen classifies the FANCA gene-disease relationship as DEFINITIVE. The packet's inheritance field lists autosomal recessive inheritance. GeneReviews states that heterozygous carriers are not at risk for autosomal recessive FA. Regarding genotype and phenotype, GeneReviews notes that the clinical spectrum of FA remains heterogeneous and that, in general, null variants are associated with a more severe phenotype than hypomorphic variants. For FANCA specifically, GeneReviews describes conflicting reports on whether homozygous null variants are associated with earlier-onset anemia and higher leukemia incidence, notes that other FANCA variants have been associated with slower hematologic disease progression, and reports that one National Cancer Institute cohort found a higher frequency of solid tumors in individuals with pathogenic variants in the exon 27-30 C-terminal region of FANCA, a region described as functionally critical for localization of the protein to the nucleus.

GeneReviews states that diagnostic criteria were agreed upon at a 2014 consensus conference and updated in 2020, and refers to the Fanconi Anemia Clinical Care Guidelines. It lists suggestive clinical findings (short stature, abnormal skin pigmentation, skeletal malformations, microcephaly, genitourinary anomalies, ocular manifestations, and otic anomalies or hearing loss), laboratory findings (macrocytosis, increased fetal hemoglobin, and cytopenia), and pathology findings (progressive bone marrow failure, aplastic anemia, myelodysplastic syndrome, leukemia, and early-onset solid tumors). It states that the diagnosis is established in a proband by either increased chromosome breakage and radial forms on cytogenetic testing of lymphocytes with diepoxybutane and mitomycin C, or identification of biallelic pathogenic or likely pathogenic variants in a gene known to cause FA. GeneReviews adds that alternative cell types such as skin fibroblasts can be tested when lymphocyte results are normal or inconclusive and mosaicism is suspected, that variants of uncertain significance cannot confirm or rule out the diagnosis, and that absence of a known family history does not preclude the diagnosis.

The packet contains no FDA-approved treatment record for this condition. Its orphan drug listing includes Fancalen, a lentiviral vector containing the FANCA gene, sponsored by Rocket Pharmaceuticals, Inc., with status DESIGNATED; an orphan designation does not constitute FDA approval. GeneReviews states that treatment guidance was agreed upon at a 2014 consensus conference and updated in 2020. Under targeted therapies, GeneReviews lists androgens, granulocyte colony-stimulating factor (G-CSF), and hematopoietic stem cell transplantation (HSCT), describing HSCT as the only curative therapy for the hematologic manifestations of FA, namely aplastic anemia, myelodysplastic syndrome, and acute myeloid leukemia. GeneReviews reports that androgens improve red blood cell and platelet counts, at least transiently, in approximately 50% of individuals and that G-CSF improves neutrophil count in some individuals; it also describes androgen side effects including virilization and liver toxicity. GeneReviews describes a multisystem evaluation after diagnosis involving growth, musculoskeletal, genitourinary, endocrine, eye, hearing, developmental, cardiac and vascular, gastrointestinal, hematology and oncology, and genetic counseling assessments, along with a separate surveillance table covering growth, endocrine, eye, hearing, developmental, blood count, bone marrow, liver, and gynecologic topics. Dosing details in the source are not reproduced here.

The packet does not certify survival figures or life expectancy for this condition. GeneReviews describes the natural history in terms of progressive bone marrow failure manifesting as pancytopenia and cancer susceptibility, with solid tumor incidence described in its cohort data as rising from around age 20 years in individuals with exon 27-30 FANCA variants. GeneReviews also reports that the clinical spectrum is heterogeneous and that some individuals have neither physical abnormalities nor bone marrow failure.

The packet lists clinical trial records associated with this condition; the following registry details are drawn from it. NCT03206086, a Phase 2 study of eltrombopag for Fanconi anemia, sponsored by the National Heart, Lung, and Blood Institute, active but not recruiting, 2018-11-02 to 2028-08-01. NCT05236764, a study of haploidentical hematopoietic cell transplantation using TCR alpha/beta and CD19 depletion, sponsored by Baylor College of Medicine, active but not recruiting, 2023-12-06 to 2027-05-23. NCT05687149, a study defining the natural history of squamous cell carcinoma in Fanconi anemia, sponsored by the National Cancer Institute, recruiting, 2023-03-23 to 2035-12-31. NCT00027274, on cancer in inherited bone marrow failure syndromes, sponsored by the National Cancer Institute, recruiting, from 2001-11-28. GeneReviews states that earlier early-phase FANCA lentiviral gene therapy trials conducted at several sites were terminated or no longer actively recruiting, and lists HSCT conditioning and T-cell depletion approaches as under investigation.